Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. (1st April 2021)

• Record Type: Journal Article
• Authors: Meregalli, C.; Bonomo, R.; Cavaletti, G.; Carozzi, V.A.
• Is Part Of: Neuroscience letters. Volume 749(2021)
• Publication Date: 2021-04-01
• Subjects: Chemotherapy-induced peripheral neuropathy (CIPN) -- Blood molecular biomarker -- Translational research -- Neurotrophins -- microRNA -- Neurofilament, metabolomics; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2021.135739
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: A mini review on the use of blood biomarkers for detecting the risk, severity and development of chemotherapy-induced peripheral neuropathy (CIPN) is provided. Results of the preclinical research and their "translability" in clinical practice are described. Results are often controversial and suggest a principle of "caution" in identifying blood biomarkers in CIPN. New technologies (metabolomics) will enable the development of increasingly sensitive and specific blood-based methods for the identification of predictive blood biomarkers in CIPN. Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) has long been recognized as a clinically significant issue in patients treated with antineoplastic drugs. This common long-term toxic side-effect which negatively impacts the outcome of the disease can lead to disability and have detrimental effects on patients' quality of life. Since axonal injury is a prominent feature of CIPN, responsible for several sensory symptoms, including pain, sensory loss and hypersensitivity to mechanical and/or cold stimuli in the hands and feet, neurophysiological assessments remain the gold standard for clinical diagnosis of CIPN. Given the large impact of CIPN on cancer patients, there is increasing emphasis on biomarkers of adverse outcomes in safety assessment and translational research, to prevent permanent neuroaxonal damage. Since the results on reliable blood molecular markers for axonal degeneration are still controversial, here we provide a brief overview of blood molecular biomarkers used for assessing and/or predicting CIPN in preclinical and clinical settings.